BHVN Stock Recent News

BHVN LATEST HEADLINES

BHVN Stock News Image - InvestorPlace

If you follow Warren Buffett's advice of being greedy when others are fearful, then it probably makes sense to consider biotech stocks to buy on the dip. Primarily, the thesis centers on the underlying necessity of the ecosystem.

InvestorPlace 2024 Apr 26
BHVN Stock News Image - CNBC Television

Vlad Coric, Biohaven CEO, joins 'Fast Money' to discuss the weight loss drug wars and the company's experimental obesity drug.

CNBC Television 2024 Mar 25
BHVN Stock News Image - InvestorPlace

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

InvestorPlace 2024 Jan 25
BHVN Stock News Image - InvestorPlace

Everyone knows that America has a major obesity problem. Because of this, new anti-obesity drugs are going to generate a great deal of revenue and profits their companies.

InvestorPlace 2024 Jan 25
BHVN Stock News Image - PRNewsWire

NEW HAVEN, Conn. , Jan. 2, 2024 /PRNewswire/ -- Biohaven Ltd.

PRNewsWire 2024 Jan 02
BHVN Stock News Image - Zacks Investment Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Zacks Investment Research 2023 Nov 16
BHVN Stock News Image - Zacks Investment Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Biohaven Ltd. (BHVN) could be a great choice.

Zacks Investment Research 2023 Nov 06
BHVN Stock News Image - Zacks Investment Research

Here is how Biohaven Ltd. (BHVN) and Blueprint Medicines (BPMC) have performed compared to their sector so far this year.

Zacks Investment Research 2023 Oct 31
BHVN Stock News Image - Zacks Investment Research

Biohaven Ltd. (BHVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move.

Zacks Investment Research 2023 Oct 19
BHVN Stock News Image - Zacks Investment Research

Biohaven (BHVN) gains on preliminary data from a pre-clinical study on its pipeline candidate BHV-1300 targeting various autoimmune diseases.

Zacks Investment Research 2023 Sep 28
10 of 50